Ear stimulation may ease depression in addiction treatment

NCT ID NCT07814755

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether a handheld device that delivers mild electrical pulses to the ear can be used at home by adults receiving treatment for substance use disorder. Participants use the device for about 60 minutes a day for 30 days. The study measures whether people can stick with the routine and tolerate the stimulation, and it explores whether the device is linked to changes in depression, anxiety, sleep, and craving.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcutaneous auricular vagus nerve stimulation delivered through an ear electrode
What this could lead to
If it works, this could offer a drug-free, home-based way to ease depression and anxiety for people in treatment for substance use disorder.
What could go wrong
This is a small pilot study focused on whether people can use the device and tolerate it, not whether it treats depression. Any symptom changes may be placebo or unrelated, and the device can cause ear discomfort, skin irritation, or headaches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able and willing to provide informed consent. * 18 to 60 years of age. * History of substance use disorder involving illicit substances, such as opioids, stimulants, or sedatives. * Currently enrolled in treatment for substance use disorder or actively seeking treatment. * Score of 11 or greater on the Patient Health Questionnaire-9 (PHQ-9), indicating at least moderate depression symptoms. * If taking medication for depression, anxiety, or sleep, on a stable dose for at least 2 weeks before the baseline visit, when feasible. * Able to read, speak, and understand English well enough to complete study procedures and questionnaires.16 17• Willing and able to comply with study visits and study procedures for approximately 30 days. Exclusion Criteria: * Currently participating in another research study that includes an active treatment or intervention. * Diagnosis of a neurological disorder, such as Parkinson's disease. * Permanent implanted metal or electronic device near the ear, including certain hearing, heart, or nerve stimulation devices. * Previous surgery involving the vagus nerve. * Resting heart rate less than 50 beats per minute. * Severe coronary artery disease or heart attack within the past 5 years. * Active infection, skin condition, or skin breakdown on or near the outer ear where the device would be placed. * History of trigeminal neuralgia within the past year. * Pregnant, planning to become pregnant during the study, or suspected to be pregnant. * Current severe or unstable psychiatric condition that would interfere with participation, such as active psychosis or acute suicidal risk. * Acute intoxication or severe withdrawal symptoms at screening or baseline that would interfere with study participation. * Significant abnormalities of the outer ear that would interfere with placement or use of the study device. * Current use of another neuromodulation therapy, such as transcranial magnetic stimulation (TMS) or vagus nerve stimulation. * Court-mandated addiction treatment. * Incarcerated individuals. * Unable to provide informed consent or comply with study procedures. * Any medical, psychiatric, or social condition that, in the opinion of the investigator, would make participation unsafe or interfere with study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Substance use disorder (SUD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.